Exact Mass: 609.2927

Exact Mass Matches: 609.2927

Found 297 metabolites which its exact mass value is equals to given mass value 609.2927, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Ergocristine

C35H39N5O5 (609.2951)

Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5, 12 and 2 positions, respectively, and oxo groups at positions 3, 6, and 18. It is a natural ergot alkaloid. D018373 - Peripheral Nervous System Agents CONFIDENCE Claviceps purpurea sclerotia relative retention time with respect to 9-anthracene Carboxylic Acid is 0.992 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.987 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.984

Tubocurarine

(1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁸,²².0²⁷,³¹.0¹⁶,³⁴]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-15-ium

C37H41N2O6+ (609.2964)

Tubocurarine is only found in individuals that have used or taken this drug. It is a neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae. [PubChem]Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarines positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents > M03AA - Curare alkaloids D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists

Macoline

C37H41N2O6+ (609.2964)

Dexniguldipine

3-((4,4-Diphenyl-1-piperidinyl)propyl)-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate hydrochloride

C36H39N3O6 (609.2839)

tiamulin fumarate

Thiamutilin fumarate

C32H51NO8S (609.3335)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic

Ergocristine

N-[7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

C35H39N5O5 (609.2951)

Niguldipine(+)

3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-4,5-dihydropyridine-3,5-dicarboxylate

C36H39N3O6 (609.2839)

2alpha,10beta-diacetoxy-9alpha-hydroxy-5alpha-(3-dimethylamino-3-phenylpropanoyl)oxy-3,11-cyclotax-4(20)-en-13-one

C35H47NO8 (609.3302)

irciniastatin A

C31H47NO11 (609.3149)

fluevirosine D

C36H39N3O6 (609.2839)

fluevirosine A

C36H39N3O6 (609.2839)

4-(2-{6-amino-2-[1-(2-amino-2-carboxy-ethylamino)-2-carboxy-ethyl]-5-methyl-pyrimidine-4-carbonylamino}-3-hydroxy-3-(1(3)H-imidazol-4-yl)-propionylamino)-3-hydroxy-2-methyl-pentanoic acid

C24H35N9O10 (609.2507)

C31H47NO11

C31H47NO11 (609.3149)

Destruxin D2

C29H47N5O9 (609.3374)

C34H47N3O7 (609.3414)

(2E,4E,7E,9S)-10-[(4S,4aR,6R,8S,8aR)-4-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-6-yl]-9-hydroxydeca-2,4,7-trienoic acid

(2E,4E,7E,9S)-10-[(4S,4aR,6R,8S,8aR)-4-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-6-yl]-9-hydroxydeca-2,4,7-trienoic acid

C31H47NO11 (609.3149)

3-demethylchaxamycin B

C34H43NO9 (609.2938)

(2E,4E)-10-[(4S,4aR,6R,8S,8aR)-4-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-6-yl]-9-oxodeca-2,4-dienoic acid

NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively[1]. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models[2].

C35H39N5O5 (609.2951)

(2r)-3-[(3s,6s,9s,16s,21as)-1,10-dihydroxy-3,6-diisopropyl-5,8,9-trimethyl-4,7,14,17-tetraoxo-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecan-16-yl]-2-methylpropanoic acid

(2r)-3-[(3s,6s,9s,16s,21as)-1,10-dihydroxy-3,6-diisopropyl-5,8,9-trimethyl-4,7,14,17-tetraoxo-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecan-16-yl]-2-methylpropanoic acid

C29H47N5O9 (609.3374)

3-{1,10-dihydroxy-3,6-diisopropyl-5,8,9-trimethyl-4,7,14,17-tetraoxo-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecan-16-yl}-2-methylpropanoic acid

C29H47N5O9 (609.3374)

(3s,6s,9s,15s,20as)-1,4,7,10,13-pentahydroxy-6-(1h-indol-3-ylmethyl)-3,15-diisopropyl-9-methyl-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C31H43N7O6 (609.3275)

(1r,2r,3r,4r,7s,9r,10r,11r,14s)-2,10-bis(acetyloxy)-3-hydroxy-4,14,15,15-tetramethyl-8-methylidene-13-oxotetracyclo[9.3.1.0¹,⁹.0⁴,⁹]pentadecan-7-yl (3r)-3-(dimethylamino)-3-phenylpropanoate

C35H47NO8 (609.3302)